1Day Sooner

1daysooner.org · American English

We envision a world where the risks taken by research participants are honored through maximally efficient and equitable use of […]

rss2 wordpress content atom dc sy

Open the feed

https://www.1daysooner.org/feed/

Last post: Sep 10, 2026
Posts in 24 h · 7 days · 30 days: 0 · 0 · 2
Our last check: Answering
Served from: United States
Site title: 1Day Home - 1Day Sooner
Text score at discovery: 10,432
Format: rss2
Features in the feed: content, atom, dc, sy
Community: wordpress

Posts

What our queue read from this feed. Open one to read it here, or go to the site that published it.

Meet Tabitha Kisakye: Passionate about participant-centered trial design
Sep 10, 2026 · original
When Tabitha Kisakye explains her willingness to volunteer for medical research, she emphasizes that she made her choice “to benefit very vulnerable populations in our community.” Tabitha, who has a degree in public health and who volunteers at a hospital in Jinja City, has had a level of success in relaying this message. “ When you… talk to them and show them the direction you see it, then they start to appreciate it ,” she says of those with whom she’s discussed clinical trial participation. Her training in public health played no small role in her own decision to participate in a clinical trial, and it continues to inform her approach to advocacy. Tabitha was in university when she learned researchers were looking for healthy volunteers for a schistosomiasis clinical trial. She first heard about the trial from one of her professors: “I got the information from a credible source, someo
Secure Africa’s Health Infrastructure Through Sustained Investment in AMA
Aug 26, 2026 · original
The African Medicines Agency (AMA) has been widely celebrated as a turning point for African regulatory sovereignty. Headquartered in Kigali, Rwanda, and part of the African Union (AU), it exists to harmonize regulatory standards, accelerate approvals, and orchestrate emergency responses across the continent. But while politically significant, AMA is still assembling the machinery for most of its functions. As AMA moves from mandate to implementation, potential donors should treat its build-out as a high-leverage foundational investment for the future where pandemics are more common and where AI-enabled R&D accelerates the discovery of biomedical discovery. AMA itself must also show that it can turn new investments into emergency response architecture. The case for AMA as infrastructure Across Africa’s regulatory landscape, there are tens of thousands of medicine registration application
Meet Marcus Dahl: Supporting Research He Believes In
Jul 27, 2026 · original
Marcus Dahl, an Australian living and working in the UK, decided to join his first clinical trial in about five minutes. A friend at Oxford’s school of public health had forwarded him a recruitment newsletter. “She said, this looks like… [a] thing you would do,” he recalls. She was right. He clicked the link and signed up. The study was a COVID-19 human challenge trial run at Oxford in 2021. In a challenge study, a small number of healthy, closely monitored volunteers are deliberately exposed to a pathogen so researchers can study how the disease behaves and how to defend against it. In the case of a COVID-19 trial, that meant a seventeen-day quarantine in a hospital isolation room. But Marcus nonetheless found enrolling to be an easy decision. “The COVID pandemic was killing millions of people. It was a massive global challenge… leading researchers in Oxford were trying to figure it out
Meet the Team: Zacharia Kafuko, 1Day Africa Director
Jul 9, 2026 · original
This post is part of a series spotlighting the members of 1Day Sooner’s team. They explain how we work toward our shared mission, and offer a window into our organizational culture for those interested in joining us as volunteers, partners, or colleagues. What was the trajectory that brought you to 1Day Sooner? I’m a biochemist by training, and I was living and working in Seychelles when the COVID-19 pandemic started. I came across an article on the BBC about a call for human challenge trial volunteers, so I read the article and I thought about it. A couple of days later, I signed up to be infected with COVID-19. If my involvement could somehow contribute to finding a vaccine quicker, then I thought that would be something worth doing. In my head, the science made sense — I understood disease mechanisms and biochemistry well enough to defend it to myself — but honestly, I think what real
Meet Elizabeth Rouha: Making Research Participation Less Intimidating
Jun 11, 2026 · original
Elizabeth Rouha learned about the clinical trial she would later join in an unusual place: “I was at a restaurant in Leiden, and there was a poster in the toilet,” she said. The poster was recruiting healthy volunteers for a challenge study using Clostridioides difficile , the leading cause of hospital-acquired diarrhoea. The placement made her laugh. But the study itself also sparked her curiosity. The study was run by Leiden University Medical Center and it was the first time healthy participants would be experimentally exposed to C. difficile in a challenge model. The bacterium lives harmlessly in many people’s guts, but for others it causes serious illness that recurs despite treatment. The trial set out to understand why. Elizabeth enrolled in the trial for two immediate reasons. The first was her straightforward excitement about its potential impact. She wanted to contribute to sci
Meet Roopesh Chavda: A Healthy Participant Turned Advocate
May 12, 2026 · original
Roopesh Chavda is an engineer with a background in mathematics, and the kind of person who responds to a crisis by researching what can be done to overcome it. In August 2020, as COVID-19 reshaped daily life and scientists raced to catch up, he was doing his own reading about how vaccines work and what it would take to bring one forward. “I just wanted to have the most information about how we can get out of this,” he recalls. Through his reading, he realized that he might be in a position to help. He signed up with 1Day Sooner that same month, hoping to enroll in a Controlled Human Infection Model (CHIM) study as a healthy volunteer. Originally from the United Kingdom and now based in France, Roopesh went on to take part in two COVID-19 CHIM trials run by Imperial College London. Each involved a 16-day inpatient quarantine. Together, they shaped how he thinks about research participatio
Meet the Team: Paul Zimmer-Harwood, Research Lead for Clinical Trials
May 7, 2026 · original
This post is the first in a series spotlighting the members of 1Day Sooner’s team. They will explain how we work toward our shared mission, and offer a window into our organizational culture for those interested in joining us as trial volunteers, colleagues, or research partners. What was the trajectory that brought you to 1Day Sooner? I regularly volunteered to be a research participant as an undergraduate; although not in clinical trials specifically. Then, during my PhD program, when I studied physiology and human genetics at Oxford, I continued to volunteer for studies. One was a two-week metabolism experiment that had me on an exercise bike for two hours every morning at 70% of my max heart rate, before breakfast, occasionally with blood draws and muscle biopsies mid-ride. I thought it would be a nice way to get my exercise out of the way, but instead I ended up needing a daily desk
Meet Angelique Mseteka: A Participant in Malawi’s First CHIM Trial
Apr 7, 2026 · original
Angelique Mseteka is a registered nurse based in Salima, Malawi. When she heard about a clinical trial studying pneumococcal vaccines in 2021, she had both personal and professional reasons to pay attention. She understood the science, and she knew the children that pneumonia was killing. They were members of her community. The more she learned about the trial, the more convinced she became of its importance. The study was the Pneumococcal Conjugate Vaccine (PCV) efficacy trial at the Malawi Liverpool Wellcome Programme — the first Controlled Human Infection Model (CHIM) trial ever conducted in Malawi. In a CHIM study, healthy adult volunteers are deliberately exposed to a pathogen under close medical supervision to generate precise immunological data. For Angelique, that meant having a small amount of Streptococcus pneumoniae — the bacterium behind pneumonia — introduced into her nose i
R21 Price Cut Unlocks $1 Billion for Malaria Vaccination in Africa
Dec 8, 2025 · original
By Zacharia Kafuko (Director of 1Day Africa) and Ollie Sayeed, PhD The international vaccine provider Gavi and the UN children’s agency UNICEF announced on Sunday that the price of the R21 malaria vaccine will fall from $3.90 to $2.99 within the next year. R21 is manufactured by the Serum Institute of India, the world’s largest vaccine manufacturer with a pioneering role in high-volume, low-cost pharmaceuticals production. The 23% drop in price is fantastic news, and should soon significantly help to accelerate the fight against malaria. According to 1Day Africa’s modelling, on top of the 57 million doses that have already been allocated since 2023 based on Gavi’s shipment reports , an extra 360 million doses are needed to vaccinate every child currently between five and 36 months old in malarial areas of Africa. This volume of doses will cover 90 million children at four doses per child
Ripple effects: How U.S. FDA layoffs threaten global health in low- and middle-income countries and weaken US competitiveness
May 28, 2025 · original
By Philip Kenol & Enlli Lewis The recent staffing cuts at the U.S. Food and Drug Administration (FDA), which affected roughly 20 percent of its workforce, have prompted concerns about the agency’s ability to fulfill its mission. The cuts would severely impact U.S. companies and U.S. global leadership in the biomedical space. The global implications would be even more grievous—particularly for low- and middle-income countries (LMICs) that depend on the FDA’s regulatory leadership. Many LMICs and other countries rely on the FDA’s assessments, approvals, and post-market surveillance data to inform their own regulatory decisions. These programs, often referred to as “reliance programs,” streamline national approval processes by referencing trusted decisions from agencies like the FDA. As the agency grapples with significant staffing reductions, there could be ripple effects on these internat
Building on the success of Operation Warp Speed
Mar 10, 2025 · original
Operation Warp Speed (OWS) was a groundbreaking public-private partnership that accelerated the development of COVID-19 vaccines, setting a model for how the U.S. government can drive innovation in critical technologies. 1Day Sooner’s recently released memo, “Building on the Success of Operation Warp Speed,” explores how OWS principles can be applied beyond emergencies, particularly in biomedical innovation. Key Insights Project NextGen: A Flawed Successor? The Biden Administration’s Project NextGen, a $5 billion initiative to support next-generation COVID-19 vaccines and treatments, was intended as an OWS successor. However, unlike OWS, it lacked clear leadership, a time-bound goal, and coordination across agencies such as the FDA and the Department of Defense (DoD). To build a true OWS 2.0, we recommend narrowing scope, funding real world evidence and transparency, recruiting private-s
Cost-effectiveness of malaria interventions: a systematic review
Mar 7, 2025 · original
Authored by The 1Day Africa research team. This project was a collaboration by Ollie Sayeed, Isla Gibson, Hannah Greene, Iain Macleod Briongos, Karam Elabd, David Tellett, Ryan Duncombe, and Julia Murdza. Introduction Malaria continues to carry a large disease burden, with an estimated 249 million cases and 608,000 deaths worldwide as of 2022. Affordability is a crucial factor in the fight against malaria, as the disease is endemic primarily in low-income regions. The global priority should be to decrease the incidence and burden of this disease, with the long-term goal of eliminating malaria country by country and eventually achieving global eradication. The WHO recommends several malaria prevention measures, but they make clear that none of these disease control interventions are sufficient to serve as a stand-alone intervention. Effective malaria control requires a multipronged approa

Discovered by the rss-feed-index crawler, which checks each feed at most once a month.

Same record as JSON: https://api.agentalog.com/api/feeds/fd_1daysooner_org_9d80a3bc70ef0fe6. More from this site: 1daysooner.org in the Feeds tab.